The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Drug: oxaliplatin     Quarter: 2016Q3

Total Records: 864     Number of Pages: 44

DRUGNAME PT EventCount
OXALIPLATIN. Subileus 3
OXALIPLATIN. Sudden death 3
OXALIPLATIN. Transaminases increased 3
OXALIPLATIN. Tumour associated fever 3
OXALIPLATIN. Tumour lysis syndrome 3
OXALIPLATIN. Unresponsive to stimuli 3
OXALIPLATIN. Urticaria 3
OXALIPLATIN. Vaginal haemorrhage 3
OXALIPLATIN. Venoocclusive liver disease 3
OXALIPLATINE Febrile bone marrow aplasia 3
OXALIPLATINE TEVA Ischaemic cerebral infarction 3
Oxaliplatino SUN 5 mg/ml, concentrato per soluzione per infusione Hypotension 3
OXALIPLATIN (Manufacturer unknown) Leukopenia 2
OXALIPLATIN (Manufacturer unknown) Nerve injury 2
OXALIPLATIN (Manufacturer unknown) Neuropathy peripheral 2
OXALIPLATIN (Manufacturer unknown) Pigmentation disorder 2
Oxaliplatin (Unknown) Circulatory collapse 2
Oxaliplatin (Unknown) Drug hypersensitivity 2
Oxaliplatin (Unknown) Neuropathy peripheral 2
OXALIPLATIN 100MG/20ML Stridor 2

Total Records: 864     Number of Pages: 44